‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the […] Continue reading -> Mandates or Markets? Geopolitical Rift Impairs Pandemic Preparedness as Crisis Funds Hit ‘Dangerous Lows’ 26/05/2026 Felix Sassmannshausen WHO emergency funds are running low, and global health leaders are concerned about a systemic paralysis in pandemic preparedness. In high-level discussions in Geneva, experts explored the geopolitical rifts, pitting the Global South’s demand to treat pandemic tools as legally binding “public goods” against a European push for market-driven surge financing. As a severe Ebola […] Continue reading -> World Health Organization Gives Stamp of Approval to First Malaria Treatment for Young Infants 06/05/2026 Elaine Ruth Fletcher The World Health Organization has ‘pre-qualified’ Coartem® Baby, the first-ever malaria treatment for young infants of 4.5 kilograms or less. The combination treatment, now being rolled out in Ghana, aims to fill a longstanding gap in treatments available for children under the age of 5, who constitute three quarters of the estimated 610,000 malaria deaths […] Continue reading -> Unlocking the Power of the Private Sector for Stronger Health Systems 06/03/2026 Elaine Ruth Fletcher As USAID programmes funding vital treatments for HIV/AIDS, malaria, maternal and child health, and other critical needs were imploding across Africa last year, a for-profit social enterprise startup geared up for its first real test. Using medicines procurement as its lever, the Swiss-based startup Axmed called for a radical reboot of national systems — to […] Continue reading -> Intellectual Property Dispute Stalls WHO Decision on Global AMR Strategy 04/02/2026 Felix Sassmannshausen A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading -> EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
Mandates or Markets? Geopolitical Rift Impairs Pandemic Preparedness as Crisis Funds Hit ‘Dangerous Lows’ 26/05/2026 Felix Sassmannshausen WHO emergency funds are running low, and global health leaders are concerned about a systemic paralysis in pandemic preparedness. In high-level discussions in Geneva, experts explored the geopolitical rifts, pitting the Global South’s demand to treat pandemic tools as legally binding “public goods” against a European push for market-driven surge financing. As a severe Ebola […] Continue reading -> World Health Organization Gives Stamp of Approval to First Malaria Treatment for Young Infants 06/05/2026 Elaine Ruth Fletcher The World Health Organization has ‘pre-qualified’ Coartem® Baby, the first-ever malaria treatment for young infants of 4.5 kilograms or less. The combination treatment, now being rolled out in Ghana, aims to fill a longstanding gap in treatments available for children under the age of 5, who constitute three quarters of the estimated 610,000 malaria deaths […] Continue reading -> Unlocking the Power of the Private Sector for Stronger Health Systems 06/03/2026 Elaine Ruth Fletcher As USAID programmes funding vital treatments for HIV/AIDS, malaria, maternal and child health, and other critical needs were imploding across Africa last year, a for-profit social enterprise startup geared up for its first real test. Using medicines procurement as its lever, the Swiss-based startup Axmed called for a radical reboot of national systems — to […] Continue reading -> Intellectual Property Dispute Stalls WHO Decision on Global AMR Strategy 04/02/2026 Felix Sassmannshausen A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading -> EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
World Health Organization Gives Stamp of Approval to First Malaria Treatment for Young Infants 06/05/2026 Elaine Ruth Fletcher The World Health Organization has ‘pre-qualified’ Coartem® Baby, the first-ever malaria treatment for young infants of 4.5 kilograms or less. The combination treatment, now being rolled out in Ghana, aims to fill a longstanding gap in treatments available for children under the age of 5, who constitute three quarters of the estimated 610,000 malaria deaths […] Continue reading -> Unlocking the Power of the Private Sector for Stronger Health Systems 06/03/2026 Elaine Ruth Fletcher As USAID programmes funding vital treatments for HIV/AIDS, malaria, maternal and child health, and other critical needs were imploding across Africa last year, a for-profit social enterprise startup geared up for its first real test. Using medicines procurement as its lever, the Swiss-based startup Axmed called for a radical reboot of national systems — to […] Continue reading -> Intellectual Property Dispute Stalls WHO Decision on Global AMR Strategy 04/02/2026 Felix Sassmannshausen A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading -> EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
Unlocking the Power of the Private Sector for Stronger Health Systems 06/03/2026 Elaine Ruth Fletcher As USAID programmes funding vital treatments for HIV/AIDS, malaria, maternal and child health, and other critical needs were imploding across Africa last year, a for-profit social enterprise startup geared up for its first real test. Using medicines procurement as its lever, the Swiss-based startup Axmed called for a radical reboot of national systems — to […] Continue reading -> Intellectual Property Dispute Stalls WHO Decision on Global AMR Strategy 04/02/2026 Felix Sassmannshausen A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading -> EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
Intellectual Property Dispute Stalls WHO Decision on Global AMR Strategy 04/02/2026 Felix Sassmannshausen A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading -> EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
Experts Outline How To Strengthen Trusted Health Knowledge Worldwide 21/11/2025 Maayan Hoffman Global health knowledge is expanding faster than ever, but so are confusion and inequity over who can access trustworthy information and use it to improve their lives. In a live recorded discussion at the World Health Summit in Berlin, featured in the latest Global Health Matters podcast, Joy Phumaphi, executive secretary of the Africa Leaders […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
WHO Includes Popular Anti-Obesity Drugs on Essential Medicines List for Diabetes Control 05/09/2025 Elaine Ruth Fletcher WHO’s 2025 Essential Medicines Lists (EML), published Friday, has included the active ingredients in popular weight loss drugs like Ozempic and Wegovy – semaglutide or other comparable GLP-1 receptor agonists – in a recommendation that recognizes the growing importance of the drugs in clinical treatment of diabetes worldwide. These drugs, as well as new PD-1/PD-L1 […] Continue reading -> WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts
WHO Awards Top-Level Recognition to Regulatory Authorities in Canada, UK and Japan 08/08/2025 Editorial team The World Health Organization (WHO) has designated government regulatory authorities in Canada, Japan, and the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. The recognition widens the pool of WHO-recognized authorities significantly beyond the previously recognized authorities in Europe, the United […] Continue reading -> Posts navigation Older posts